IE66904B1 - Qantification of nucleic acid molecules and the reagent Kit Used - Google Patents
Qantification of nucleic acid molecules and the reagent Kit UsedInfo
- Publication number
- IE66904B1 IE66904B1 IE49687A IE49687A IE66904B1 IE 66904 B1 IE66904 B1 IE 66904B1 IE 49687 A IE49687 A IE 49687A IE 49687 A IE49687 A IE 49687A IE 66904 B1 IE66904 B1 IE 66904B1
- Authority
- IE
- Ireland
- Prior art keywords
- fragment
- gene
- nucleic acid
- test
- standard
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 81
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 80
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 80
- 239000003153 chemical reaction reagent Substances 0.000 title claims abstract description 18
- 238000012360 testing method Methods 0.000 claims abstract description 88
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 48
- 238000009396 hybridization Methods 0.000 claims abstract description 43
- 238000000034 method Methods 0.000 claims abstract description 41
- 108020004999 messenger RNA Proteins 0.000 claims abstract description 18
- 230000003321 amplification Effects 0.000 claims abstract description 12
- 238000003199 nucleic acid amplification method Methods 0.000 claims abstract description 12
- 239000000523 sample Substances 0.000 claims description 139
- 239000012634 fragment Substances 0.000 claims description 64
- 239000013612 plasmid Substances 0.000 claims description 37
- 108020004414 DNA Proteins 0.000 claims description 31
- 108091008146 restriction endonucleases Proteins 0.000 claims description 31
- 239000013598 vector Substances 0.000 claims description 18
- 108010022394 Threonine synthase Proteins 0.000 claims description 16
- 102000004419 dihydrofolate reductase Human genes 0.000 claims description 13
- 108700024542 myc Genes Proteins 0.000 claims description 13
- 101150074155 DHFR gene Proteins 0.000 claims description 8
- 108700020796 Oncogene Proteins 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 7
- 238000011144 upstream manufacturing Methods 0.000 claims description 7
- 102000053602 DNA Human genes 0.000 claims description 6
- 241000713333 Mouse mammary tumor virus Species 0.000 claims description 6
- 238000002955 isolation Methods 0.000 claims description 5
- 101710135898 Myc proto-oncogene protein Proteins 0.000 claims description 4
- 102100038895 Myc proto-oncogene protein Human genes 0.000 claims description 4
- 101710150448 Transcriptional regulator Myc Proteins 0.000 claims description 4
- 229920002477 rna polymer Polymers 0.000 claims description 4
- 238000004445 quantitative analysis Methods 0.000 claims description 3
- 239000013600 plasmid vector Substances 0.000 claims 2
- 102100030708 GTPase KRas Human genes 0.000 claims 1
- 101710113436 GTPase KRas Proteins 0.000 claims 1
- 101100237844 Mus musculus Mmp19 gene Proteins 0.000 claims 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 claims 1
- 244000046052 Phaseolus vulgaris Species 0.000 claims 1
- 238000011002 quantification Methods 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 description 45
- 239000000243 solution Substances 0.000 description 12
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 6
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 101150026150 mt gene Proteins 0.000 description 5
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 5
- 238000013519 translation Methods 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 239000000020 Nitrocellulose Substances 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 229920001220 nitrocellulos Polymers 0.000 description 4
- 239000002773 nucleotide Substances 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004925 denaturation Methods 0.000 description 3
- 230000036425 denaturation Effects 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical group N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- CKTSBUTUHBMZGZ-SHYZEUOFSA-N 2'‐deoxycytidine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 CKTSBUTUHBMZGZ-SHYZEUOFSA-N 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 2
- CKTSBUTUHBMZGZ-UHFFFAOYSA-N Deoxycytidine Natural products O=C1N=C(N)C=CN1C1OC(CO)C(O)C1 CKTSBUTUHBMZGZ-UHFFFAOYSA-N 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 101150039798 MYC gene Proteins 0.000 description 2
- 208000024556 Mendelian disease Diseases 0.000 description 2
- 238000000636 Northern blotting Methods 0.000 description 2
- 102000052708 Recessive Genes Human genes 0.000 description 2
- 108700005079 Recessive Genes Proteins 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000011543 agarose gel Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 210000000349 chromosome Anatomy 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- -1 nucleoside triphosphates Chemical class 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 108010051423 streptavidin-agarose Proteins 0.000 description 2
- 239000001226 triphosphate Substances 0.000 description 2
- 235000011178 triphosphate Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 206010008805 Chromosomal abnormalities Diseases 0.000 description 1
- 208000031404 Chromosome Aberrations Diseases 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 101150017040 I gene Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 238000000376 autoradiography Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229910052793 cadmium Inorganic materials 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 108091092356 cellular DNA Proteins 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000008175 fetal development Effects 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229940094991 herring sperm dna Drugs 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention is related to the quantification of certain nucleic acid molecules, particularly the degree of amplification of genes and/or corresponding messenger RNA molecules using the sandwich or solution hybridization method, and the reagent kit used. The determination is carried out by comparing the number of the test nucleic acid molecules potentially present in several copies in given unit to the number of chosen standard nucleic acid molecules advantageously present in a constant number per same unit.
[CA1287558C]
Description
The invention relates to the quantification of certain nucleic acid molecules, particularly the degree of amplification of genes and/or corresponding messenger RNA molecules using the sandwich or solution hybridization method, and the reagent kit used.
The number of copies of individual genes in the genome is usually constant. In some instances there is only one gene per haploid genome and in others several. under certain circumstances the number of copies may change. The amplification of certain genes has for example been found to be associated with the development of cancer. It is also known that external factors such as pharmaceuticals and metals cause certain genes to be amplified. For the development of a disease, the faulty or enhanced expression level of a gene, such as an oncogene, i.e. the quantity of messenger RNA in the cell, is of major importance. Increased numbers of some chromosomes is the cause of certain hereditary diseases or other disturbances, whereas some hereditary diseases only require duplication of one recessive gene. In all such instances it is important to determine the number of chromosomes or genes present.
The number of certain DNA molecules, for example the degree of amplification of given genes, is currently determined by digesting the extracted DNA to be studied by means of restriction enzymes and by separating the nucleotide fragments according to length by agarose gel electrophoresis. Subsequently the single-stranded DNA is transferred and affixed to a nitrocellulose filter, where hybridization takes place using the gene to be studied or part of the gene as a probe. The results are obtained by autoradiography (Southern, J. Mol. Biol 98, pp. 503-517, 1975). In each parallel analysis, the quantity of cellular DNA is the same.
The intensities of the hybridisation bands, i.e. the signals are compared and the ratios between the copy numbers of the genes under study in the test samples are deduced. The method only yields approximate results. Likewise, RNA is measured using Northern-blotting or dot-blotting methods. These methods are quantitatively very inaccurate (Thomas, Methods in Enzymol., 100, pp. 255-266, 1983).
Known methods, such as the Southern and Northern blotting methods, are slow and difficult to perform. Since they only yield approximate results their diagnostic value is doubtful in cases in which it is important to know the number of certain nucleic acid molecules per given unit, such as a cell.
The present invention now provides an accurate and rapid quantitative method of nucleic acid molecule determination which is also faster and simpler to perform than those currently used. It can be used for cancer and prenatal diagnostics, for detecting agents which cause gene amplification and for demonstrating the development of e.g. drug resistance as well as for the determination of the expression level of messenger RNA.
In accordance with the present invention, there is provided a quantitative method for the determination of nucleic acid molecules by sandwich solution hybridization, the method comprising determining the number of nucleic acid molecules per given unit by comparing the number of test nucleic acid molecules potentially present in several copies in the unit to the number of chosen standard nucleic acid, molecules advantageously present in a constant number in the same unit, wherein the nucleic acids present in the sample (a) are rendered, if necessary, into a form whereby they can participate in the hybridization reaction, any nucleic acids potentially disturbing the hybridisation reaction being rendered, if necessary, into a form whereby they cannot interfere with the hybridisation test; and (b) are brought into contact, either undivided or, when necessary divided, with at least one test probe pair sufficiently homologous to the nucleic acid potentially present in several copies and with at least one chosen and suitable standard probe pair sufficiently homologous to the nucleic acid molecule advantageously present in a constant number, the detector probes of the test probe pair and standard probe pair being labelled with a detectable label and the capturing probes having been affixed to a suitable carrier or a substance having been affixed to the capturing probes which enables isolation of the resulting hybrids; and wherein (c) after hybridization, the test hybrid and standard hybrid are separated when necessary and the attached label is measured and the number of nucleic acid molecules per given unit is obtained by comparing the test and standard nucleic acid numbers .
The present Invention provides also a reagent kit for use in such a method, the kit comprising at least one test probe pair and at least one standard probe pair, the detector probes of both the test probe pair and the standard probe pair being labelled with a suitable label and the capturing probes having been affixed to a suitable carrier or a substance having been affixed to the capturing probes, enabling isolation of sandwich hybrids.
In. the present contextt a nucleic acid molecule is considered to be of a size ranging from a sequence of 10 - 12 nucleotides to a gene containing several thousand nucleotides. It can also mean a messenger RNA or a nucleotide sequence considerably longer than a single gene, i.e. an amplicone.
In the method of the invention, the determination of test and standard nucleic acids is carried out using an otherwise normal sandwich hybridisation described, for example, in U.S. Patent No. 4,485,539 or a solution hybridisation described in British Patent Application No. GB 2,169,403. Such sandwich and solution hybridization have the distinction of being quantitative (Virtanen et al., Lancet .1, pp. 381-383, 1983).
The reagents, or probes, used in the method of the invention may be prepared using recombinant-DNA techniques, from nucleic acids sufficiently homologous to the test and standard nucleic acids. Sufficiently homologous nucleic acids can also be prepared synthetically and semisynthatically.
The test and standard nucleic acids may be isolated directly from cells and identified by various hybridization techniques. Such test and standard nucleic acids are however also available commercially and from various gene banks. Test and standard nucleic acid may be either DNA or RNA.
Probe pairs suitable for the sandwich or solution hybridization are prepared from nucleic acids sufficiently homologous to the test and standard nucleic acids by recombinant-DNA techniques. The relevant nucleic acids are digested by suitable restriction enzymes; at least two of the resulting restriction fragments situated relatively close together are cloned to at least two suitable vectors. One of the fragments, the detectors probe, is labelled with a suitable detectable label and the other, the capturing probe, is either affixed to a suitable carrier or an substance is affixed to it, which substance enables separation of the resulting hybrid from the hybridization mixture by means of another substance, such as the complementary component of an affinity pair.
The test and standard probe pairs can be assembled into suitable reagent kits wherein the test and standard probe pairs are both DNA or RNA, or the test probe pair is DNA and the standard probe pair RNA or vice versa. The pre- and further treatment of samples prior to hybridization and the hybridization conditions should therefore comply with the probe pairs used in the test.
The method of the present invention is particularly suitable for determining the number of nucleic acid molecules directly from cellular homogenates. The method may of course also be used for the determination of purified or pure nucleic acids. However, before carrying out the method of the invention, the most suitable pretreatment of the nucleic acid sample should be selected» It is possible to carry out both DNA and RNA determinations using the method of the invention. Deoxyribonucleic acids are denatured to obtain single strands if necessary. Singlestranded messenger RNA molecules potentially disturbing the hybridization test can be hydrolyzed, for example by alkaline boiling. The sample is not denatured in connection with ribonucleic acid determinations since the double-stranded deoxyribonucleic acid does not interfere with RNA determination. It is of course possible to disrupt the DNA with deoxyribonuclease or alter it either chemically or mechanically so that it cannot participate in the hybridization reaction. Therefore in connection with DNA and RNA determinations a suitable method for further treatment of the sample must be selected or, alternatively, this further treatment may be omitted. The choice of a suitable method for the further treatment is of course dependent on the method used for the preliminary treatment of the nucleic acid sample.
Numerous methods of pre- and further treatment of nucleic acid samples have been described in the literature,, enabling the most suitable method to be chosen in each case.
Determinations in which both the test and standard nucleic acids are either DNA or RNA can be performed using an undivided sample. Determinations in which the test nucleic acids are DNA and the standard nucleic acids RNA or vice versa must be performed using a divided sample, as different methods for further treatment are necessary. The sample may of course be divided even if the test and standard nucleic acids are of the same nucleic acid type.
The hybridisation test itself is performed by bringing the undivided sample solution into contact simultaneously with at least one test probe pair and one standard probe pair. If the sample solution has been divided it is brought separately into contact with at least one test probe pair and one standard probe pair. In such instances, the quantity of test nucleic acid is determined in one reaction vessel and the quantity of the standard nucleic acid in the other.
Regardless of whether the sample is divided or notf hybridisation is allowed to take place in the most advantageous conditions and time in each case. Once the reaction(s) has/have taken place, the resulting test and standard hybrids are separated from the hybridisation mixture(s) by the carrier and washed, or by an isolation agent such as the complementary member of an affinity pair. The label attached to the test and standard hybrids is measured and the result compared with standard curves. In this way the number of nucleic acid molecules to be studied can be determined per selected unit.
The method of the invention is of practical diagnostic value, particularly in the detection of some types of cancer. In small cell lung carcinoma, the c-myc gene is often amplified and its level of expression considerably higher than in normal tissue. In cases of neuroblastoma the N-myc gene is amplified.
The method of the present invention can also be used for demonstrating the mutagenic or carcinogenic effects of certain agents or the development of drug resistance. It is known that external pressure of selection can result in enhanced expression of a certain gene. In the treatment of cancer, cells develop resistance to a given drug by amplification of the gene, the expression product of which inactivates the drug. One such case is methotrexate which induces amplification of the gene for dihydrofolate reductase (DHFR). A further example is amplification of the gene for metallothionine under the influence of cadmium.
The expression level of a gene is important from the point of view of the phenotype and function of the cell. This can be investigated by measuring the quantity of messenger RNA which correlates to the quantity of protein coded by it. The transcription product of an oncogene determines the way in which it will ultimately be expressed.
The expression levels of an oncogene vary depending on the cell type, differentiation level and phase of development of the cell. For example, at a certain, stage of fetal development, the c-myc oncogene is copied rapidly, whereas at another stage this is very slow. The degree of amplification often correlates with the level of expression of the gene, although the latter may significantly increase without the former. In such instances the role of an oncogene is best determined by measuring its level of expression rather than the number of copies. In some instances, quantitative determination of the messenger RNA may be simpler and handier than quantification of the gene product itself. As an example the c~myc oncogene, a labile protein readily coagulated by heat, can be mentioned.
The method of the invention can also be used for identifying numerical chromosomal abnormalities such as Down's syndrome. In prenatal diagnostics it is also possible to determine whether the fetus is defective, i.e. homozygous for some recessive gene.
The method of the invention and the nucleic acid reagents used in the method are described in greater detail below.
EXAMPLE 1 .Quantification of am amplified oncogen® a) Nucleic acid reagents and their preparation STANDARD PROBES Cell standard nucleic acid.. The c-Ki-rasI gene is present in all human cells. The probe pairs for sandwich hybridization were prepared by subcloning the HindiII fragment of the c-Kiras I gene, measuring 3.8 kb in length, the restriction map of which has been described by Chang et al., PNAS 79, pp. 484852, 1982. The fragment is available e.g. cloned into the pBR322 plasmid (ATCC 41032) and can be obtained e.g. from the ATCC culture collection.
Further treatment of the cell . standard nucleic acid. The pBR322 clone described above was treated with Bglll and HindiII restriction enzymes and the resulting fragments were isolated from the agarose gel; purified fragments located close together were subcloned into two suitable vectors for preparation of the detector and capturing probes.
Standard detector -probe, A Bglll-Bglll fragment measuring about 1.1 kb in length was subcloned into the BamHI restriction enzyme site of the pBR322 plasmid and labelled by nick-translation with 125I-lahelled dCTP.
Standard capturing probe. The Bgl II-Hindl 11 fragment of about 0.5 kb was inserted into the M13 mplO and mpll phage vectors between the restriction sites of BamHI and Hindlll restriction enzymes and affixed to a nitrocellulose filter (150 ng DNA/dia 1 cm).
TEST PROBES Test, nucleic acid-. A probe pair for sandwich hybridization was prepared from a cloned c~myc gene which can be obtained for example, from the ATCC culture collection (ATCC 41010). The restriction map of gene has been described by Watt et al,, PNAS 80, pp. 5307-6311, 1983.
Further. treatment of the test nucleic acid. The c~myc gene was treated with Hindlll, Xbal and Pstl restriction enzymes and the fragments isolated from the agarose gel, purified and subcloned into suitable vectors in order to prepare the detector and capturing probes.
Test detector probe.. The single-stranded tails of the HindiII-Xbal restriction fragment of the c-myc gene, measuring 3.7 kb in length, were rendered double-stranded by DNA polymerase. The Hindlll linkers were inserted by T4-DNAligase into the resulting blunt-end DNA fragments; after phenol extraction the DNA was treated with the Hindlll restriction enzyme. The DNA fragment was subsequently cloned into the pBR322 plasmid at the restriction site of the Hindlll restriction enzyme and labelled by nick-trans lation with 1251labelled dCTP.
Test capturing, probe. The 1.1 kb Xbal-Pstl fragment of the c-myc gene was cloned into the M13 mplO and mpll phage cloning vectors between the restriction sites of the Xbal and Pstl restriction enzymes and affixed to the nitrocellulose filter (150 ng DNA/dia 1 cm) . b) Determination of the standard curve.
The sample used for determination of the standard curve consisted of an alkaline-denatured pBR322 clone of the c-myc gene. The sandwich hybridization solution to which the above test probes were added consisted of 4 x SSC, 1 x Denhardt solution, 200 Mg/ml herring sperm DNA and 0.2 % SDS.
Hybridization took place at 65°C for 17 - 19 hours, whereafter the filters were washed in the wash solution (0.1 x SSC 0.2 % SDS) at 50°C. The label attached to the sandwich hybrids was then counted in the gamma counter.
Table 1 53Mpl® molecules;/test com c-mtyc-f liter 0 40 10s 75 5 χ 10δ 190 107 340 108 2200 c) Determination of the _ nwibeg of genes ., The samples comprises 1) cells from a human placenta and 2) Colo 320 cells, which can be obtained e.g. from the ATCC culture collection (ATCC-CCC220). DNA was isolated from both samples, and the same quantity of cell DNA, denatured by alkaline boiling, was added to both tests. Alkaline denaturation hydrolyzed any RNA present in the sample.
The test was performed by adding to each sample both the c-myc and c-Ki-rasI filters and the two labelled reagents, enabling both the standard and test DNA to be measured for each sample. On the basis of c-Ki-rasI determinations, each test was found to contain the same quantity of DNA and it can be deduced that the c-myc gene in Colo 320 cells is present in about 16 - 20 higher copy number than in the normal situation. The results are shown in Table 2.
Table 2 Sample c-Ki-rasI filter c-wc filter cpm* cw* number Human placental cells 486 340 107 Colo 320 cells 432 3205 1.6 χ 108 *the reading obtained from the blank filter has been subtracted from the readings.
EXAMPLE 2 Quantification of amplified gene a) Nucleic acid reagents and their preioaraxion STANDARD PROBES Cell standard nucleic .acid. The control nucleic acid was taken from the promoter area of the metallothionine gene in the mouse,, i.e. the MT gene, and the DNA immediately upstream of it. The structure of the MT gene has been described by Pavlakis and Hamer, PNAS ,80, pp. 397-401, 1983. The reference nucleic acid fragments is available e.g. cloned into the pBPVMMTneo(432-12) vector (ATCC 37224) and can be obtained, for example, from the ATCC culture collection.
Further treatment.· of cell staaidard nucleic acid. The MT gene described above was treated with Kpnl, Bglll and EcoRI restriction enzymes for subcloning into the pAT153 plasmid. The Kpnl tail was converted into a HindxII tail with a linker.
Standard detector orohe. The EcoRI-Kpnl-(Hindlll) fragment measuring about 1.2 kb and located upstream of the promoter area of metallothionine gene was cloned to the pAT153 plasmid between the restriction sites of the EcoRI and HindiII restriction enzymes and labelled by nick-translation with 3Zp-labelled nucleoside triphosphates.
Standard capturing The 0.8 kb ΚρηΙ-BglII fragment comprising the promoter area of the metallothionine gene and the area upstream of it was cloned into the M13 mpl8 and Ml3 mpl9 phage vectors between the restriction sites of the Kpnl and BamHI restriction enzymes and affixed to the nitrocellulose filter.
TEST PROBES Test nucleic acid. The probe pair for the sandwich hybridization test was prepared using the commercially available pMTVdhfr plasmid (Bethesda Research Laboratories, product No. 5369SS), the structure of which is described by Lee et al., Nature 294, pp. 228-232, 1981.
Further treatment of test nucleic acid. The pMTVdhfr plasmid containing cDNA of the dihydrofolate reductase (DHFR) gene was treated with HindiIϊ and Bglll restriction enzymes.
Test detector probe. The Hindlll-Bglll fragment, measuring 0.75 kb and corresponding to the area coding for the DHFR gene of the pMTVdhfr plasmid, was inserted into the plasmid pAT153 vector between the restriction sites of the HindiII and BamHI restriction enzymes and labelled by nick-translation with 32P-labelled nucleoside triphosphates.
Test caotwrinor probe. A Hindlll fragment measuring 1.4 kb taken from the MMTV gene area of the pMTVdhfr plasmid was cloned into the M13 mpl8 and M13 mpl9 phage vectors. b) PeteraaLination of the standard curve The sample used for the test was purified DNA from the pMTVdhfr plasmid. The test itself was carried out as described in Example lb except that a liquid scintillation counter was used for counting. The resulting standard curve is shown in Table 3.
Table 3 Samole corn molecules/test DHFR filter 0 17 10s 45 3 x 10s 79 107 210 c) Determination of the am&er, of cremes Cell lines (derived from the mouse fibroblast cell N1H 3T3 and available from the ATCC culture collection under the number CRD 1658) which has been transfected with different quantities of cDNA corresponding to the mRNA of the DHFR gene were cultured on cell culture plates and used as the sample. The cells were lysed using sodium dodecyl sulphate and their DNA was sheared by squeezing through a fine hypodermic needle from a syringe. A 250 μΐ sample corresponding to about 106 cells was taken from the homogenate and 50 μΐ NaOH added. The sample was boiled and neutralized with acetic acid and the hybridization mixture. The total volume was 0.5 ml. All the probes described above were added simultaneously and a socalled blank filter was added as a background control. Hybridization, washing and label counting were done as in Example lb except that a liquid scintillation counter was used for counting. The results are shown in Table 4 .
IS Table 4- Call MT ¢40. ai eatts mm cam* in th® ean’ ¢40. es moteadss ¢40. c: ist As samps»» Cap'S® Cosnral csil (hio mt=F^eOm) 22 1.03 x 1G8 21 < IC? - Lists 1 138 0.S X id® CD 3si id* 3 Uew II 210 X 10s 7S2 5x 107 40 * cpm: the reading given by the blank filter has been subtracted.
The MT gene is an internal marker which measures the number of cells present in a sample. The results show that in this test 106 cells gave an MT-specific signal of 165 + 20 cpm. The DHFR reagents measure the quantity of DHFR-cDNA. The number of cells was deduced from the MT-specific signal. It was thus possible to determine the number of DHFR-cDNA copies in different cell lines as shown in Tabla 4.
ESAMPLS 3.
Quantification of messenger RNA a) Nucleic acid reagents and their preparation Using the test probes described in Example 2 it is also possible to measure the quantity of mRNA derived from DHFRcDNA. The structure of the pMTVdhfr plasmid is such that transcription of the DHFR gene begins at the MMTV promoter. The resulting messengers are about 1.0 kb in length. Of this, about 0.25 kb are derived from the MMTV promoter area and the rest from DHFR-cDNA (Lee et al., Nature 294, ρρ. 228-232, 1981).
STANDARD PROBES The cell standard nucleic acid, standard detector and standard capturing probe were as described in Example 2.
TEST PROBES The test nucleic acid, test detector and test capturing probe were as described in Example 2. b) D@termd.:aatiosl· of the standard curve The sample used for standard curve determination consisted of messenger RNA corresponding to the dihydrofolate reductase gene produced by in vitro transcription. The DNA needed for transcription was prepared by subcloning the 1.4 kb HindlH fragment of the MMTV promoter of the pMTvdhfr plasmid and the 0,75 kb Hindlll-Bglll fragment (DHFR-cDNA) next to each other into the pSP64 plasmid (Promega Biotec) between the restriction sites of the HindlH and BamHI restriction enzymes. The sample RNA was stored in 0.2 % SDS aqueous solution.
The sandwich hybridization test was carried out as described in Examples lb and 2b but denaturation was omitted.
Table 5 Sarnole molecules/test com DHFR filter 0 20 5 χ 10δ 65 107 130 5 χ 107 390 10s 653 c) Determination of the number of Bbesseaoer RHIA molecules The number of. messenger RNA molecules corresponding to the DHFR gene was determined from the cell lines described in Example 2.
The cells were lysed using sodium dodecyl sulphate and their DNA was sheared slightly by squeezing through a fine hypodermic needle from a syringe. A 250 μΐ sample of the homogenate was taken corresponding to about 5 χ 106 cells. The homogenate was then added to the sandwich hybridization test without denaturation. Sandwich hybridization took place as described in Examples 2c and lb, except that only the DHFR probes were added to the hybridisation solution. In a parallel sample of 250 μΐ of homogenate, the cell number was determined using the MT probe as described in Example 2c.
The results are shown in Table β.
Table δ Cei ΜΐΓ epes® Os· «wjCKTsr to ift® swwto DHFR esa* Six e# «ifeoAs to tJ&e sampfe Ife. P*3i &cfl llto© IJ 390 as x mi 11465 345x t©5 « 10» HI 430 <2 x -4300 2 x lie? see 10 *cpm: The reading given by the blank filter has been subtracted.
The results showed that cell line I produced per cell about 100 messenger RNA molecules from the DHFR genes and cell line II produced about 500 messenger RNA molecules from the DHFR genes.
EXAMPLE 4.
Quantification of amplified gene by solution hybridization. a) Nucleic .acid reagents and their preparation STA3HDASD PROBES The cell standard nucleic acid, standard detector and standard capturing probe were as described in Example 2. The 1.2 kb EcoRI-Kpnl-(Hindlll) fragment in pAT153 was labelled by nick·· translation with 125I-labelled deoxycytidine. The 0.8 kb KpnlBglll fragments in ill3 mpl8 and Ml3 mpl9 were modified with biotin using the Photoprobe™ reagent (Vector Laboratories, CA, USA, product No SP-1000).
TEST PROBES The test nucleic acid, test detector and test capturing probe were as described in Example 2. The 0.75 kb Hindlll-Bglll fragment in pAT153 was labelled with 125I-labelled deoxycytidine. The 1.4 kb HindlH fragments in M13 mpl8 and Ml3 mpl9 were biotinylated using Photoprobe™ as above. b) Determination of the standard curves A cell standard curve was prepared using a known amount of cells, from which the hybridization signal was measured using the standard probes recognizing the MT-gene. A test nucleic acid standard curve was prepared with the pMTVdhfr plasmid and the test probes recognizing this plasmid. Hybridizations were carried out in 200 μΐ of a solution consisting of Ο.β M NaCl, 20 mM phosphate buffer, pH 7.5, 1 mM EDTA, 4% polyethylene glycol (PEC 6000) for 1.5 hours at 70°C. After the reaction 50 μΐ of streptavidin-agarose (Betheseda Research Laboratories, Maryland, USA, product No. 5942SA), and 1 M NaCl, 10 mM sodium phosphate, pH 7.5, 1 mM EDTA was added to a final volume of 500 μΐ. The hybrids were collected on the streptavidinagarose at 37°C for 15 min. The agarose was washed once for 5 min. with the buffered 1 M NaCL solution at 37°C and twice for 2 min. with 15 mM NaCl, 1.5 mM sodium citrate at 55°C. The amount of bound hybrids was determined by measuring the agarose in a gamma counter. (Syvanen et al., Nucleic Acids Res. 14., 5037-5048, 1986). The results are shown in table 7 and 8.
Table 7 Sasrole con® cells/test MT probes 0,8 x 10s 162 1,6 x 106 216 3 x 10s 298 Table 8 .Sasroie molecules/test DHFR probes 10s 148 5 x 10s 394 5 x 107 2240 c) Determination of the number of ©panes..
Samples of the cell lines described in Example 2 were treated in a similar way, except that the volume per sample corresponding to approximately 2 x 106 cells was 125 μΐ. The determinations of number of cells and number of test nucleic acid molecules were carried out in separate vials by adding the cell sample, the appropriate detector and capturing probes, and the components of the hybridization mixture to a final volume of 200 μΐ. Control assays without cell standard or test DNA were included. Hybridization, collection of hybrids, washing and measurement was done as described in Example 4b. The results were read from standard curves prepared in parallel as described in Example 4b. The results are shown in Table 9.
Table 9 _ Cell MT DHFR cpe* No of cells in the sample com* SiO. of No. of Molecules copies in the sample Control cell 253 2.3 x 10s 73 < I05 - Lin© I 210 1.5 x 10s 233 3.8 x 10s 3 Line II 237 2.1 x 10s 3059 8.8 x IO7 42 * cpsas values from control assays without cell standard or test nucleic acid have been subtracted-
Claims (14)
1. A quantitative method for the determination of nucleic acid molecules by sandwich or solution hybridization, the method comprising determining the number of nucleic acid molecules per given unit by comparing the number of test nucleic acid molecules potentially present in several copies in the unit to the number of chosen standard nucleic acid molecules advantageously present in a constant number in the same unit, wherein the nucleic acids present in the sample (a) are rendered, if necessary, into a form whereby they can participate in the hybridization reaction, any nucleic acids potentially disturbing the hybridization reaction being rendered, if necessary, into a form whereby they cannot interfere with the hybridization test; and (b) are brought into contact, either undivided or, when necessary divided, with at least one test probe pair sufficiently homologous to the nucleic acid potentially present in several copies and with at least one chosen and suitable standard probe pair sufficiently homologous to the nucleic acid molecule advantageously present in a constant number, the detector probes of the test probe pair and standard probe pair being labelled with a detectable label and the capturing probes having been affixed to a suitable carrier or a substance having been affixed to the capturing probes which enables isolation of the resulting hybrids, and wherein (c) after hybridisation, the test hybrid and standard hybrid are separated when necessary and the attached label is measured and the number of nucleic acid molecules per given unit is obtained by comparing the test and standard nucleic acid numbers.
2. A method according to claim 1, wherein the test and standard nucleic acids are deoxyribonucleic acids.
3. A method according to claim 1, wherein the test nucleic acid is ribonucleic acid and the standard nucleic acid is deoxyribonucleic acid.
4. A method according to claim 1, wherein the test and standard nucleic acids are ribonucleic acids. 5. Detector probe of the test probe pair is a recombinant plasmid comprising a 0.75 kb Hindlll-Bglll fragment coding for the DHFR gene of the pMTVdhfr plasmid, the fragment having been subcloned into the pAT153 plasmid vector between the restriction sites of the HindiIX and
5. A method according to claim 1, wherein the test nucleic acid is deoxyribonucleic acid and the standard nucleic acid is ribonucleic acid. δ.
6. A method according to any one of claims 1 to 3, wherein the detector probe of the standard probe pair is a recombinant plasmid comprising a 1.1 kb BglH-BglH fragment of the HindHI fragment of the human c-Ki-rasI gene, the HindHI fragment being cloned into the pBR322 plasmid and the Bglll-Bglll fragment being subcloned into the restriction site of the BamHl restriction enzyme of the pBR322 plasmid, and the capturing probes are recombinant phages comprising a 0.5 kb BglH-HindiII fragment of the HindHI fragment of the human c-Ki-rasI gene, the HindHI fragment being cloned into the pBR322 plasmid and the Bglll-Hindlll fragment being subcloned into the Ml 3 mplO and Ml 3 mpll phage vectors between, the restriction sites of the BamHl and HindHI restriction enzymes and wherein the probes are brought, either individually or together with the test probe pair, into contact with an undivided or when necessary divided nucleic acid sample.
7. A method according to any one of claims 1 to 3, wherein the detector probe of the standard probe pair is a recombinant plasmid comprising a 1.2 kb EcoRIKpnl(Hindili) fragment from upstream of the promoter area of the mouse metallothionine gene, which fragment has been subcloned into the pAT153 plasmid between the restriction sites of the EcoRI and Hindili restriction enzymes, and the capturing probes are recombinant phages comprising a 0.8 kb ΚρηΙ-BglII fragment from the promoter arsa of the metallothionine gene and the area upstream of it, the fragment having been subcloned into the Ml3 mp!8 and Ml3 mpl9 phage vectors between the restriction sites of the Kpnl and BamHI restriction enzymes, and wherein the probes are brought, either individually or together with the test probe pair, into contact with an undivided or when necessary divided nucleic acid sample.
8. A method according to claim S or claim 7, wherein in order to determine the degree of amplification of the c-myc oncogene and/or the number of messenger RNA molecules corresponding to that gene, the detector probe of the test probe pair is a recombinant plasmid comprising a 3.7 kb Hindlll-Xbal fragment of the c-myc gene, the fragment being subcloned into the pBR322 plasmid at the restriction site of the Hindili restriction enzyme, and the capturing probes are recombinant phages comprising a 1.1 kb Xbal-Pstl fragment of the c-myc gene, the fragment having been subcloned into the Ml 3 mplO and Ml 3 mpll vectors between the restriction sites of the Xbal and Pstl restriction enzymes, and wherein the probes are brought, either individually or together with the standard probe pair, into contact with an undivided or when necessary divided nucleic acid sample.
9. A method according to claim S or claim 7, wherein in order to determine the degree of amplification of the dihydrofolate reductase or DHFR gene and/or the number of messenger RNA molecules corresponding to that gene, the
10. A reagent kit for the quantitative determination of 20 nucleic acid molecules by the method of claim 1, the kit comprising at least one test probe pair and at least one standard probe pair, the detector probes of both the test probe pair and the standard probe pair being labelled with a suitable label and the capturing probes having 25 been affixed to a suitable carrier or a substance having been affixed to the capturing probes, enabling isolation of sandwich hybrids. 10 BamHI restriction enzymes, and the capturing probes are recombinant phages comprising a 1.4 kb HindlH fragment of the MMTV gene area of the pMTVdhfr plasmid, the fragment having been subcloned into the Ml3 mpl8 and Ml3 mpl9 phage vectors at the restriction site of the HindiII 15 restriction enzyme and wherein the probes are brought, either individually or together with the standard probe pair, into contact with an undivided or when necessary divided nucleic acid sample.
11. A reagent kit according to claim 10, wherein the detector probe of the test probe pair used for the determination 30 of the degree of amplification of the c-myc oncogene and/or the number of messenger RNA molecules corresponding to that gene is a recombinant plasmid comprising a 3.7 kb Hindlll-Xbal restriction fragment of the c-myc gene, the fragment having been subcloned into the pBR322 plasmid at the restriction, site of the Hindi 11 restriction enzyme, the capturing probes are recombinant phages comprising a 1.1 kb Xbal-Pstl fragment of the c-myc gene, the fragment having been subcloned into the Ml 3 mplO and Ml 3 xnpll phage vectors between the restriction sites of the Xbal and Pstl restriction enzymes, the detector probe of the standard probe pair is a 1.1 kb Bglll-Bgll'I fragment of the Hindi 11 fragment of the human c-Ki~rasI gene, the Hindlll fragment having been cloned into the pBR322 plasmid and the Bglll-Bglll fragment having been subcloned into the pBR322 plasmid at the restriction site of the BamHI restriction enzyme, and the capturing probes are recombinant phages comprising a 0.5 kb BgllX-Hindlll fragment of the Hindlll fragment of the c-Ki-ras! gene, the Hindlll fragment having been subcloned into the pBR322 plasmid of the c-Ki-rasI gene, and the Bglll-Hindi 11 fragment having been subcloned into the Ml3 mplO and Ml3 mpll phage vectors between the restriction sites of the BamHI and Hindlll restriction enzymes .
12. A reagent kit according to claim 10, wherein the detector probe of the test probe pair used for determination of the degree of amplification of the dihydrofolate reductase of DHFR gene and/or the number of messenger RKA molecules corresponding to that gene is a recombinant plasmid comprising a 0.75 kb HindiII-Bglll fragment coding for the DHFR gene of the pMTVdhfr plasmid, the fragment having been subcloned into the pAT!53 plasmid vector between the restriction sites of the Hindlll and BamHI restriction enzymes, the capturing probes are recombinant phages comprising a 1.4 kb Hindlll fragment of the MMTV gene area of the pMTVdhfr plasmid, the fragment having bean subcloned into the Ml3 rap 18 and Ml3 mpl9 phage vectors at the restriction site of the Hindlll restriction enzyme, the detector probe of the standard probe pair is a recombinant plasmid comprising a 1.2 kb EcoRI-Kpnl fragment from upstream of the promoter area of the mouse metallothionine gene, the fragment having been subcloned into the OAT153 plasmid between the restriction sites of the EcoRI and Hindlll restriction enzymes, and the capturing probes are recombinant phages comprising a 0.8 kb Kpnl-Bglll fragment of the metallothionine gene formed by the promoter area and the area upstream of it, the fragment having been subcloned into the Ml 3 mpl8 and Ml 3 mpl9 phage vectors between the restriction sites of the Kpnl and BamHI restriction enzymes.
13. A method according to claim 1, substantially as hereinbefore described.
14. A reagent kit according to claim 10, substantially as hereinbefore described.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FI860836A FI76119C (en) | 1986-02-27 | 1986-02-27 | Quantitative determination of nucleic acid molecules and reagent packaging used in the process |
Publications (2)
Publication Number | Publication Date |
---|---|
IE870496L IE870496L (en) | 1987-08-27 |
IE66904B1 true IE66904B1 (en) | 1996-02-07 |
Family
ID=8522222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE49687A IE66904B1 (en) | 1986-02-27 | 1987-02-26 | Qantification of nucleic acid molecules and the reagent Kit Used |
Country Status (26)
Country | Link |
---|---|
JP (1) | JPS62205800A (en) |
KR (1) | KR870008033A (en) |
AT (1) | AT393511B (en) |
AU (1) | AU603562B2 (en) |
BE (1) | BE1001168A4 (en) |
CA (1) | CA1287558C (en) |
CH (1) | CH675593A5 (en) |
DD (1) | DD270383A5 (en) |
DE (1) | DE3706285A1 (en) |
DK (1) | DK174784B1 (en) |
ES (1) | ES2061411A6 (en) |
FI (1) | FI76119C (en) |
FR (1) | FR2594849B1 (en) |
GB (1) | GB2187283B (en) |
HU (1) | HU201808B (en) |
IE (1) | IE66904B1 (en) |
IL (1) | IL81695A (en) |
IS (1) | IS3197A7 (en) |
IT (1) | IT1202581B (en) |
LU (1) | LU86792A1 (en) |
NL (1) | NL195097C (en) |
NO (1) | NO175380C (en) |
NZ (1) | NZ219421A (en) |
PT (1) | PT84368B (en) |
SE (1) | SE468816B (en) |
ZA (1) | ZA871401B (en) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5714380A (en) | 1986-10-23 | 1998-02-03 | Amoco Corporation | Closed vessel for isolating target molecules and for performing amplification |
IL86724A (en) | 1987-06-19 | 1995-01-24 | Siska Diagnostics Inc | Method and kits for the amplification and detection of nucleic acid sequences |
EP0304845A3 (en) * | 1987-08-28 | 1991-03-06 | Profile Diagnostic Sciences Inc. | Method and kit for assaying gene expressions |
DE68921918T2 (en) * | 1988-05-09 | 1995-09-07 | Univ Temple | Procedure for predicting the effectiveness of antineoplastic treatment in individual patients. |
AU629845B2 (en) * | 1988-08-30 | 1992-10-15 | Abbott Laboratories | Detection and amplification of target nucleic acid sequences |
AU5731790A (en) * | 1989-05-18 | 1990-12-18 | United States of America, as represented by the Secretary, U.S. Department of Commerce, The | Rna probe for detecting c-fes mrna |
US5232829A (en) * | 1989-09-29 | 1993-08-03 | Hoffmann-La Roche Inc. | Detection of chlamydia trachomatis by polymerase chain reaction using biotin labelled lina primers and capture probes |
DK138090D0 (en) * | 1990-06-06 | 1990-06-06 | Novo Nordisk As | DIAGNOSTIC METHOD OF ANALYSIS |
DE69214243T2 (en) * | 1991-09-23 | 1997-02-06 | Pfizer | Methods for the detection of specific mRNA and DNA in cells |
US6300058B1 (en) | 1992-01-29 | 2001-10-09 | Hitachi Chemical Research Center, Inc. | Method for measuring messenger RNA |
GB9210916D0 (en) * | 1992-05-21 | 1992-07-08 | Isis Innovation | Nucleic acid quantification |
CA2140763A1 (en) * | 1992-07-28 | 1994-02-03 | Masato Mitsuhashi | Gene detection system |
US5580971A (en) * | 1992-07-28 | 1996-12-03 | Hitachi Chemical Company, Ltd. | Fungal detection system based on rRNA probes |
ES2055661B1 (en) * | 1993-01-20 | 1995-03-01 | Univ Malaga | DETERMINATION OF THE GENE EXPRESSION BY SPECIFIC CAPTURE OF RNA AND ITS DIRECT QUANTIFICATION BY CAPILLARY ELECTROPHORESIS IN A FREE ZONE. |
GB9309966D0 (en) * | 1993-05-14 | 1993-06-30 | Nordion Int Inc | Detection of prostrate-specific antigen in breast tumors |
GB9415489D0 (en) * | 1994-08-01 | 1994-09-21 | Nordion Int Inc | Detection of prostate-specific antigen in amniotic fluid |
AT401062B (en) * | 1994-09-26 | 1996-06-25 | Immuno Ag | Method for quantifying nucleic acids |
JP5565781B2 (en) | 2010-03-31 | 2014-08-06 | 有限会社山口ティー・エル・オー | Method for detecting pneumonia-causing bacteria using nucleic acid chromatography |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4442203A (en) * | 1981-06-30 | 1984-04-10 | Massachusetts Institute Of Technology | Gene amplification assay for detecting tumor promoters |
FI63596C (en) * | 1981-10-16 | 1983-07-11 | Orion Yhtymae Oy | MICROBIA DIAGNOSIS FOERFARANDE SOM GRUNDAR SIG PAO SKIKTSHYBRIDISERING AV NUCLEINSYROR OCH VID FOERFARANDET ANVAENDA KOMBINATIONER AV REAGENSER |
AU555146B2 (en) * | 1982-03-15 | 1986-09-11 | Trustees Of Columbia University In The City Of New York, The | Method for intorducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products materials |
CA1252046A (en) * | 1982-11-04 | 1989-04-04 | Martin J. Cline | Methods for oncogenic detection |
FI71768C (en) * | 1984-02-17 | 1987-02-09 | Orion Yhtymae Oy | Enhanced nucleic acid reagents and process for their preparation. |
US4675283A (en) * | 1984-07-19 | 1987-06-23 | Massachusetts Institute Of Technology | Detection and isolation of homologous, repeated and amplified nucleic acid sequences |
FI72146C (en) * | 1985-01-02 | 1987-04-13 | Orion Yhtymae Oy | Procedure for Identifying Nucleic Acids. |
FR2583771B1 (en) * | 1985-06-21 | 1988-12-09 | Centre Nat Rech Scient | DNA SEQUENCES OF ARCHAEBACTERIA HOMOLOGATED TO ONCOGEN V-MYC, PROTEINS ENCODED BY THESE SEQUENCES, PROCESSES FOR OBTAINING SAME AND IMMUNOLOGICAL APPLICATIONS |
-
1986
- 1986-02-27 FI FI860836A patent/FI76119C/en not_active IP Right Cessation
-
1987
- 1987-02-25 JP JP62042442A patent/JPS62205800A/en active Granted
- 1987-02-26 IE IE49687A patent/IE66904B1/en not_active IP Right Cessation
- 1987-02-26 NZ NZ219421A patent/NZ219421A/en unknown
- 1987-02-26 FR FR878702541A patent/FR2594849B1/en not_active Expired - Lifetime
- 1987-02-26 CA CA000530691A patent/CA1287558C/en not_active Expired - Lifetime
- 1987-02-26 AT AT431/87A patent/AT393511B/en not_active IP Right Cessation
- 1987-02-26 IT IT19501/87A patent/IT1202581B/en active
- 1987-02-26 KR KR870001680A patent/KR870008033A/en not_active Application Discontinuation
- 1987-02-26 IS IS3197A patent/IS3197A7/en unknown
- 1987-02-26 BE BE8700177A patent/BE1001168A4/en not_active IP Right Cessation
- 1987-02-26 SE SE8700821A patent/SE468816B/en not_active IP Right Cessation
- 1987-02-26 LU LU86792A patent/LU86792A1/en unknown
- 1987-02-26 DK DK198700993A patent/DK174784B1/en not_active IP Right Cessation
- 1987-02-26 ES ES08700776A patent/ES2061411A6/en not_active Expired - Fee Related
- 1987-02-26 DE DE19873706285 patent/DE3706285A1/en active Granted
- 1987-02-26 NO NO870794A patent/NO175380C/en unknown
- 1987-02-26 GB GB8704517A patent/GB2187283B/en not_active Expired - Lifetime
- 1987-02-26 ZA ZA871401A patent/ZA871401B/en unknown
- 1987-02-26 CH CH756/87A patent/CH675593A5/de not_active IP Right Cessation
- 1987-02-26 HU HU87750A patent/HU201808B/en unknown
- 1987-02-26 AU AU69275/87A patent/AU603562B2/en not_active Expired
- 1987-02-26 NL NL8700483A patent/NL195097C/en not_active IP Right Cessation
- 1987-02-26 PT PT84368A patent/PT84368B/en unknown
- 1987-02-27 DD DD87300286A patent/DD270383A5/en unknown
- 1987-02-27 IL IL81695A patent/IL81695A/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IE66904B1 (en) | Qantification of nucleic acid molecules and the reagent Kit Used | |
US4946773A (en) | Detection of base pair mismatches using RNAase A | |
EP0444115B2 (en) | In situ suppression hybridization and uses therefor | |
Christianson et al. | Identification of multiple transcriptional initiation sites on the yeast mitochondrial genome by in vitro capping with guanylyltransferase. | |
Klein et al. | A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia | |
US5645990A (en) | Identification and paternity determination by detecting presence or absence of multiple nucleic acid sequences | |
CN105838777A (en) | Method for monitoring secondary drug resistance of lung cancer patient to tyrosine kinase inhibitor through ddPCR technology | |
Sollner et al. | Accurate transcription of cloned Xenopus rRNA genes by RNA polymerase I: demonstration by S1 nuclease mapping | |
Uryu et al. | Research note: Determination of the sex of chickens by a biotin-labeled deoxyribonucleic acid probe | |
WO2017114011A1 (en) | Her-2 gene and/or top2a gene detection probe, preparation method therefor, and test kit | |
Kalkuhl et al. | p21Ras downstream effectors are increased in activity or expression in mouse liver tumors but do not differ betweenRas-mutated andRas-wild-type lesions | |
EP0172153A1 (en) | Polynucleotide hybridization probes | |
Minkley Jr | Transcription of the early region of bacteriophage T7: specificity and selectivity in the in vitro initiation of RNA synthesis | |
WO2017114010A1 (en) | Top2a gene detection probe, preparation method therefor, and test kit | |
Markovic et al. | A sensitive method for the detection of poly‐A tails of mRNA using a biotin‐labelled heteropolymer of dT: rA | |
Tsuchiya et al. | Characterization of a DNA uptake reaction through the nuclear membrane of isolated yeast nuclei | |
Ludwig et al. | Measurement of mRNA by solution hybridization with 32P-labelled single stranded cRNA probe (“SP6 test”). Comparison with a 32P-labelled single stranded cDNA as hybridization probe (“S1 test”) for measurement of AVP mRNA | |
WO1998048277A1 (en) | A sensitive method for measurement of telomeric dna content in human tissues | |
Bahramian et al. | Direct gene quantitation by PCR reveals differential accumulation of ectopic enzyme in rat-1 cells, v-fos transformants, and revertants. | |
CN117248017A (en) | Human NRAS gene mutation detection kit and application thereof | |
Goldenthal | Isolation and Characterization of Mitochondrial RNA Polymerase from Drosophila Melanogaster |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK9A | Patent expired |